24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Trial Profile

24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms FREEDOMS-II EXTENSION
  • Sponsors Novartis
  • Most Recent Events

    • 28 Apr 2017 Results of pooled analysis of two core studies and their respective extension studies presented at the 69th Annual Meeting of the American Academy of Neurology
    • 03 May 2014 Results from a pooled analysis of EDSS outcomes presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 25 Sep 2013 Data will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), according to a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top